Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

This study found that TNFα inhibitors can induce psoriatic alopecia, highlighting that early diagnosis and discontinuation of the drugs in some cases may prevent irreversible scalp damage.

This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.

This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.

This review discusses common skin eruptions caused by biologics in treating inflammatory bowel disease and proposes tailored therapeutic approaches for managing these adverse reactions.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This quiz based on a Journal of Investigative Dermatology article reports no new clinical results but serves as an educational tool for diagnosing scalp conditions, including scalp psoriasis and psoriatic alopecia.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

Increased pigmentation may protect skin from UVB, new targets for skin disease treatments were identified, sunscreen ingredients don't affect hormones, TNF-α inhibitors may help diabetic wounds, and certain treatments could prevent chemotherapy-induced hair loss.

This study found that 17β-estradiol inhibited RANTES production in human keratinocytes by suppressing nuclear factor κB activity, suggesting a potential mechanism for 17β-estradiol's modulation of psoriasis-related inflammation.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

This article reviews the chronic skin disorder hidradenitis suppurativa, discussing its symptoms, possible causes, and various treatment options, but reports no new clinical findings.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

Some treatments like topical oxygen and stem cells show promise for wound healing and hair growth, but evidence for modern dressings over traditional ones is limited.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

The study found that reducing testosterone in male mice through castration or androgen antagonism significantly accelerated wound healing by decreasing inflammation, suggesting a potential therapeutic target for impaired healing in elderly men.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This review discusses recent discoveries about the role of Eda and other TNF-related cytokines in skin appendage development and reports no new experimental results, highlighting developments since the last comprehensive summary in 2003.

This study describes tumor necrosis factor inhibitor-associated psoriatic alopecia, highlighting the distinctive histologic feature of sebaceous lobule atrophy, which is potentially reversible and helps differentiate it from idiopathic psoriatic alopecia.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

This study shows that macrophage-induced TNF signaling can activate hair follicle stem cells and promote new hair follicle formation after wounding by regulating AKT/β-catenin pathways.

This study observed that among male patients who experienced telogen effluvium after platelet-rich plasma treatment for androgenic alopecia, there were elevated levels of TNF-α, androgen receptors, and altered 5α-reductase gene expression, suggesting these factors as potential contributors to this unintended outcome.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.